NasdaqCM:NAOV

Stock Analysis Report

Executive Summary

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Risks

  • NanoVibronix has significant price volatility in the past 3 months.
  • NanoVibronix is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has NanoVibronix's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

7.6%

NasdaqCM:NAOV

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

-47.3%

NasdaqCM:NAOV

8.7%

US Medical Equipment

1.7%

US Market

NAOV underperformed the Medical Equipment industry which returned 8.7% over the past year.

NAOV underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

NAOVIndustryMarket
7 Day7.6%-1.2%1.2%
30 Day-10.4%1.4%4.9%
90 Day-38.7%4.8%3.7%
1 Year-47.3%-47.3%9.6%8.7%3.9%1.7%
3 Year-56.0%-56.0%70.8%65.5%47.2%37.7%
5 Yearn/a130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is NanoVibronix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NanoVibronix undervalued based on future cash flows and its price relative to the stock market?

8.61x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for NanoVibronix to establish if it is available at moderate discount.

Unable to calculate intrinsic value for NanoVibronix to establish if it is available at substantial discount.


Price Based on Earnings

NanoVibronix is loss making, we can't compare its value to the US Medical Equipment industry average.

NanoVibronix is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for NanoVibronix, we can't assess if its growth is good value.


Price Based on Value of Assets

NanoVibronix is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is NanoVibronix expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

-2.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

NanoVibronix's revenue is expected to grow significantly at over 20% yearly.

NanoVibronix is not considered high growth as it is expected to be loss making for the next 1-3 years.

NanoVibronix's revenue growth is expected to exceed the United States of America market average.

Unable to compare NanoVibronix's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare NanoVibronix's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if NanoVibronix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has NanoVibronix performed over the past 5 years?

-20.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

NanoVibronix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare NanoVibronix's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare NanoVibronix's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if NanoVibronix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if NanoVibronix has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if NanoVibronix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is NanoVibronix's financial position?


Financial Position Analysis

NanoVibronix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

NanoVibronix's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

NanoVibronix has no debt.

NanoVibronix currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

NanoVibronix has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

NanoVibronix has less than a year of cash runway based on current free cash flow.

NanoVibronix has less than a year of cash runway if free cash flow continues to grow at historical rates of 36% each year.


Next Steps

Dividend

What is NanoVibronix's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate NanoVibronix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate NanoVibronix's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as NanoVibronix has not reported any payouts.

Unable to verify if NanoVibronix's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as NanoVibronix has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of NanoVibronix's salary, the management and board of directors tenure and is there insider trading?

2.9yrs

Average management tenure


CEO

Brian Murphy (62yo)

2.9yrs

Tenure

US$590,897

Compensation

Mr. Brian M. Murphy has been the Chief Executive Officer of NanoVibronix Inc. since October 13, 2016. Mr. Murphy has over 25 years of sales, operations and general management experience in medical devices  ...


CEO Compensation Analysis

Brian's remuneration is about average for companies of similar size in United States of America.

Brian's compensation has increased whilst company is loss making.


Management Age and Tenure

2.9yrs

Average Tenure

63yo

Average Age

The tenure for the NanoVibronix management team is about average.


Board Age and Tenure

4.4yrs

Average Tenure

65.5yo

Average Age

The tenure for the NanoVibronix board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Steve Brown (63yo)

    Consultant

    • Tenure: 0.3yrs
    • Compensation: US$225.47k
  • Jay Cardwell (58yo)

    Chief Financial Officer

    • Tenure: 0.3yrs
  • Harold Jacob (65yo)

    Chief Medical Officer & Director

    • Tenure: 16yrs
    • Compensation: US$10.59k
  • Amir Rippel

    Vice President of Marketing

    • Tenure: 0yrs
  • William Stern (77yo)

    President

    • Tenure: 2.9yrs
    • Compensation: US$231.60k
  • Brian Murphy (62yo)

    CEO & Director

    • Tenure: 2.9yrs
    • Compensation: US$590.90k
  • Lindsey Harrison

    Vice President of Sales

    • Tenure: 0yrs

Board Members

  • Shalom Hirschman (83yo)

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Tom Mika (66yo)

    Independent Director

    • Tenure: 4.4yrs
  • Chris Fashek (69yo)

    Chairman of the Board

    • Tenure: 2.9yrs
    • Compensation: US$150.00k
  • Dennis Maki

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Harold Jacob (65yo)

    Chief Medical Officer & Director

    • Tenure: 16yrs
    • Compensation: US$10.59k
  • Phil Hanno

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Samuel Pinchas

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Yechezkiel Caine

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Mike Ferguson (47yo)

    Independent Director

    • Tenure: 4.4yrs
  • Brian Murphy (62yo)

    CEO & Director

    • Tenure: 2.9yrs
    • Compensation: US$590.90k

Company Information

NanoVibronix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NanoVibronix, Inc.
  • Ticker: NAOV
  • Exchange: NasdaqCM
  • Founded: 2003
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$17.396m
  • Shares outstanding: 7.19m
  • Website: https://www.nanovibronix.com

Number of Employees


Location

  • NanoVibronix, Inc.
  • 525 Executive Boulevard
  • Elmsford
  • New York
  • 10523
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NAOVNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 2015

Biography

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and p ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 01:12
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.